Selected article for: "entry process and host cell"
Author: Hsu, Shih-Hsien; Yeh, Ming-Lun; Wang, Shen-Nien
Title: New Insights in Recurrent HCV Infection after Liver Transplantation
  • Document date: 2013_4_23
    • ID: 0hbeso65_30
    Snippet: The current therapy against HCV infection, consisting of a combination of pegylated interferon (IFN) and ribavirin (RBV), is limited by resistance, adverse effects, and high costs. The absence of preventive regiment is a major limitation for patients undergoing LT for HCV-related liver failure. Moreover, accelerated progression to liver cirrhosis after graft reinfection and limited efficacy of IFN-based therapies for recurrent HCV are two major c.....
    Document: The current therapy against HCV infection, consisting of a combination of pegylated interferon (IFN) and ribavirin (RBV), is limited by resistance, adverse effects, and high costs. The absence of preventive regiment is a major limitation for patients undergoing LT for HCV-related liver failure. Moreover, accelerated progression to liver cirrhosis after graft reinfection and limited efficacy of IFN-based therapies for recurrent HCV are two major clinical issues leading to poor posttransplant outcome of the HCV recipients [80] . Thus, novel preventive and therapeutic antivirals are urgently needed. Viral entry is required for initiation, spread, and maintenance of infection. HCV entry is a multistep process orchestrated by a number of viral and host cell factors.

    Search related documents:
    Co phrase search for related documents
    • adverse effect and HCV infection: 1
    • cell factor and current therapy: 1
    • cell factor and HCV infection: 1
    • cell factor and host viral cell factor: 1, 2, 3, 4, 5, 6
    • clinical issue and HCV infection: 1, 2
    • current therapy and graft reinfection: 1
    • current therapy and HCV entry: 1, 2, 3, 4, 5
    • current therapy and HCV infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • current therapy and HCV infection current therapy: 1, 2, 3, 4, 5, 6
    • current therapy and high cost: 1, 2, 3, 4
    • current therapy and infection maintenance: 1
    • graft reinfection and HCV entry: 1, 2
    • graft reinfection and HCV infection: 1, 2, 3, 4, 5, 6, 7
    • HCV infection and high cost: 1, 2, 3